#PublicaSalutIB 🩸🖼️ Hematologia de Son Espases i Son Llàtzer participaron en el #EHA2025 Congress que se celebró en Milán https://f.mtr.cool/nkdbjozjiw @idisba.bsky.social
0
0
0
0
Hashtag
#EHA2025
Advertisement · 728 × 90
#PublicaSalutIB 🩸🖼️ Hematologia de Son Llàtzer i Son Espases varen participar a l' #EHA2025 Congress que es va celebrar a Milà https://f.mtr.cool/icobahvyga @idisbaib
0
0
0
0
New data 📝 At #EHA2025 and #18ICML, Matthew Ku and Krish Patel, respectively, presented results from a phase Ib study investigating JNJ-90014496, a CD19/CD20 bispecific CAR T-cell therapy, in patients with R/R LBCL.
Learn more: https://loom.ly/bobViGE
#Lymphoma #lymsm #MedNews #MedEd
0
0
0
0
In an insightful interview, Idoroenyi Amanam of @cityofhope.bsky.social discusses real-world data on the outcomes of US patients with lower-risk MDS treated with luspatercept in the first-line setting.
Click here to watch:
👉 buff.ly/EiFxYRa 👈
#MDSsm #HemOnc #EHA2025 #BloodSky #HemeSky #MedSky
0
0
0
0
#EHA2025 may be ending, but our virtual exhibit is still open! Browse our virtual exhibit and get 30% off & free domestic shipping using code EX58066: bit.ly/UCPEXEHA
0
1
0
0
✨ #JohnsonAndJohnson 🇺🇸 repousse la frontière des #CAR_Tcells 🧬
Lors du congrès #EHA2025 🇪🇺, J&J a dévoilé des données sur son #CAR_T 🧬 à double cible ( #CD19 + #CD20) pour le #Lymphome 🩸 à grandes cellules B R/R qui fait tourner les têtes :
2
1
1
0
Attending the Economic History Association meeting? Check out our featured books! Whether you're attending or not, you can now browse our virtual exhibit and get 30% off & free US shipping with promo code EX58066: bit.ly/UCPEXEHA #EHA2025
0
1
0
0
📝 A subgroup analysis from the phase III ECHO trial, presented by Martin Dreyling at #EHA2025, found that acalabrutinib + BR achieved a higher CR rate vs placebo + BR in patients with high-risk MCL (p < 0.0001).
More news: LymphomaHub.com
#Lymphoma #lymsm #MedNews #MedEd
0
0
0
0
🎥 Guenther Koehne presents the early findings from the Phase I/II study of donor-derived anti-CD33 CAR T-cells in patients with R/R AML following alloSCT:
👉 buff.ly/ekvp1qv 👈
#AMLsm #Leusm #Leukemia #CTSM #TrialUpdate #EHA2025 #BloodSky #HemeSky #MedSky
0
0
0
0
New data 📝 Results from a subgroup analysis of the phase III ECHO trial, presented by Martin Dreyling at #EHA2025, showed a PFS benefit with acalabrutinib + BR vs placebo + BR in patients with high-risk MCL.
Learn more: https://loom.ly/HnMZphw
#Lymphoma #lymsm #MedNews #MedEd
0
0
0
0
Next episode drops soon! Subscribers get early access!
This is the first of two highlighting the 2025 HemaSphere Awards for Top Cited paper award winners from #EHA2025 in Milan.
While you wait, enjoy a BTS look at our recent recording. Should we compile more bloopers into a longer reel?
0
0
0
0
🎥 Shaun Fleming presents early safety and efficacy findings of LAVA-1266, a CD123-targeting Vγ9Vδ2-T cell engager, in patients with R/R AML or HR-MDS:
👉 buff.ly/GIoMPtN 👈
#MDSsm #AMLsm #Leusm #Leukemia #CTSM #TrialUpdate #EHA2025 #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky
0
0
0
0
We caught up with Adam Kittai at #EHA2025 to hear about the importance of the recently published consensus guidelines for Richter’s transformation, which aim to improve patient outcomes by unifying management practices & research:
🎥 👉 buff.ly/L4eLhvD
#CLLsm #Leusm #HemOnc #BloodSky #HemeSky
0
0
0
0
At #EHA2025, Harry Erba of @dukecancer.bsky.social outlined the updated results from the Phase III QuANTUM-Wild trial evaluating quizartinib combined with chemotherapy and as single-agent maintenance in newly diagnosed FLT3-ITD-negative AML.
Watch here:
👉 buff.ly/hMASdPZ 👈
#AMLsm #Leusm #CTSM
1
0
0
0
Talquetamab/Teclistamab May Address Need for Improved Survival Outcomes in R/R Myeloma With Extramedullary Disease @clevelandclinic.bsky.social #EHA2025 #mmsm #hematology
www.onclive.com/view/talquet...
0
0
0
0
📝 The 2-year follow-up results from the phase II ELM-2 trial, presented by Stefano Luminari at #EHA2025, show odronextamab achieved a median PFS and OS of 23.0 months and 54.2 months, respectively, in patients with R/R FL.
More news: LymphomaHub.com
#Lymphoma #lymsm #MedNews #MedEd
0
0
0
0
New data 📝The 2-year follow-up results from the phase II ELM-2 trial, presented by Stefano Luminari at #EHA2025, show odronextamab achieved an ORR of 80.5% and a CR rate of 74.2% in patients with R/R FL.
Learn more: https://loom.ly/soy1sYI
#Lymphoma #lymsm #MedNews #MedEd
0
0
0
0
It was fantastic to catch up with @beksac.bsky.social at #EHA2025! Dr Beksac shared the findings of an indirect comparison using data from the DREAMM-7 & DREAMM-8 trials of BPD versus DVD in R/R #MultipleMyeloma.🩸
Watch the interview here:
🎥 buff.ly/LcnizoG
#MMSM #Myeloma #CTSM #ImmunoOnc #HemOnc
0
0
0
0
In an insightful recent interview, Jacqueline Barrientos delves into fixed-duration versus continuous treatment with venetoclax-based regimens for CLL.
🎥 Watch here:
👉 buff.ly/1hgTKwR 👈
#CLLsm #Leusm #Leukemia #HemOnc #EHA2025 #BloodSky #HemeSky #MedSky
1
0
0
0
At #EHA2025, @jahanzaibkhwaja.bsky.social of @uclh.bsky.social commented on the need for updated prognostic models in systemic light chain #amyloidosis & highlighted the identification of a “Mayo Stage IIIC” subgroup.
Click to watch:
👉 buff.ly/AGRVW53 👈
#HemOnc #BloodSky #HemeSky #MedSky
1
0
0
0
In an interview from #EHA2025, Musa Yilmaz of @mdanderson.bsky.social speaks on the efficacy of the triplet combination of decitabine, venetoclax, & quizartinib in patients with newly diagnosed FLT3-ITD–mutated AML.
Watch now:
🎥 buff.ly/LJGCKLC
#AMLsm #Leusm #Leukemia #CTSM #HemOnc #BloodSky
0
0
0
0
📝 Results from the phase III POLARGO trial, presented by Matthew Matasar at #EHA2025, found that Pola-R-GemOx vs R-GemOx improved OS and PFS in transplant-ineligible patients with R/R DLBCL.
More news: LymphomaHub.com
#Lymphoma #lymsm #MedNews #MedEd
0
0
0
0
We had the pleasure of interviewing Muhamed Baljević of @vanderbilt.edu at #EHA2025 to hear the long-term efficacy & safety data of etentamig, a BCMA-targeting bispecific antibody, in R/R #MultipleMyeloma.
Click to watch:
👉 buff.ly/I0bNLR1 👈
#MMSM #Myeloma #CTSM #ImmunoOnc #HemOnc #BloodSky
3
0
0
0
New data 📝Results from the phase III POLARGO trial, presented by Matthew Matasar at #EHA2025, show that Pola-R-GemOx improved OS in transplant-ineligible patients with R/R DLBCL vs R-GemOx (p = 0.0017).
Learn more: https://loom.ly/14mTZQs
#Lymphoma #lymsm #MedNews #MedEd
0
0
0
0
🎯Outcomes of the successful working days at the #EHA2025 Congress!
ERN-EuroBloodNet participated actively with:
📍A dedicated booth;
🎤Active participation in oral & poster sessions;
🤝The Board of Network (BoN) meeting.
eurobloodnet.eu/news/660/out...
@ec.europa.eu @euonehealth.bsky.social
0
0
0
0
🎥 A subgroup analysis of the BOSTON trial investigated the impact of selinexor dose reductions on outcomes in pts with len-refractory #MultipleMyeloma treated with the SVD regimen.
Sosana Delimpasi shared the findings at #EHA2025:
👉 buff.ly/H97ScVm
#MMSM #Myeloma #CTSM #HemOnc #BloodSky #HemeSky
1
0
0
0
Los vídeos que explican la investigación presentada en #EHA2025 ya están publicados en @ecancer.org.
Para verlos, aquí: n9.cl/aknax
0
0
0
0
📝 A phase I trial presented by Yuqin Song at #EHA2025 found that SHR2554, an EZH2 inhibitor, demonstrated antitumor activity across PTCL subtypes.
More news: LymphomaHub.com
#Lymphoma #lymsm #MedNews #MedEd
0
0
0
0
